Ritlecitinib ( PF-06651600 ) is a potent and selective JAK3 inhibitor. PF-06651600, a potent and low clearance compound with demonstrated in vivo efficacy.
*The following content is generated by AI and is for reference only.
Overview
Ritlecitinib is a selective JAK1/3 inhibitor developed for autoimmune disorders. Its core synthesis involves advanced heterocyclic coupling. Molecular formula: C26H30N8O; CAS No.: 2297457-68-2.
Application
- Alopecia areata treatment in clinical trials.
- Severe atopic dermatitis management.
- Research into other T-cell mediated inflammatory conditions.
Precautions
Contraindicated in patients with active infections. Requires strict storage below 25°C in dry, light-resistant environments. Clinical use mandates monitoring of lipid profiles and liver function.